The Asia Pacific infectious disease therapeutics market was valued at US$ 25.90 billion in 2022 and is expected to reach US$ 37.41 billion by 2030; it is estimated to register a CAGR of 4.7% from 2022 to 2030.
Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in India and South Korea, are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.
As stated by Frontiers Public Health, the winter peak of influenza coincided with the outbreak of COVID-19 in the country in 2021. According to the World Bank Country Director of China 2020, the country is at a high risk of infectious diseases due to its growing population, wildlife abundance, habitat fragmentation, and high livestock production levels.
Considering the country's growing incidence of infectious diseases, the World Bank's Board of Executive Directors approved a US$ 300 million loan for the Emerging Infectious Diseases Prevention, Preparedness and Response Project. This will help it reduce the risk of zoonotic and other emerging health threats. Thus, the rising incidence of infectious diseases and measures taken to control these diseases are expected to boost the China infectious disease therapeutics market in the coming years.
Growing Opportunities in Developing Nations Boost Asia Pacific Infectious Disease Therapeutics Market
The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response.Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in India and South Korea, are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.
Asia Pacific Infectious Disease Therapeutics Market Overview
The Asia Pacific infectious disease therapeutics market is sub-segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The market in the region is expected to grow owing to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base. The infectious disease such as influenza, hepatitis B, and infectious diarrhea are common in China and typhoid, malaria, jaundice, tuberculosis, and AIDS in India. Influenza, hepatitis B, and infectious diarrhea are the three common infectious diseases in China.As stated by Frontiers Public Health, the winter peak of influenza coincided with the outbreak of COVID-19 in the country in 2021. According to the World Bank Country Director of China 2020, the country is at a high risk of infectious diseases due to its growing population, wildlife abundance, habitat fragmentation, and high livestock production levels.
Considering the country's growing incidence of infectious diseases, the World Bank's Board of Executive Directors approved a US$ 300 million loan for the Emerging Infectious Diseases Prevention, Preparedness and Response Project. This will help it reduce the risk of zoonotic and other emerging health threats. Thus, the rising incidence of infectious diseases and measures taken to control these diseases are expected to boost the China infectious disease therapeutics market in the coming years.
Asia Pacific Infectious Disease Therapeutics Market Segmentation
The Asia Pacific infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.- Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
- In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.
- Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.
- In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.
- By country, the Asia Pacific infectious disease therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific infectious disease therapeutics market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics
5. Infectious Disease Therapeutics Market - Asia Pacific Market Analysis
6. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Drug Class
7. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Indication
8. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Route of Administration
9. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Distribution Channel
10. Asia Pacific Infectious Disease Therapeutics Market - Country Analysis
11. Infectious Disease Therapeutics Market-Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- AbbVie Inc
- Astellas Pharma Inc
- Bayer AG
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- GSK Plc
- Merck & Co Inc
- Pfizer Inc
- Shionogi & Co Ltd
